prikaz prve stranice dokumenta Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
  Preuzmi
PDF 2.11 MB
Znanstveni rad - Izvorni znanstveni rad
Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
BMJ Open, 8 (2019), 11; e021508. https://doi.org/10.1136/bmjopen-2018-021508
Sahebkar, Amirhossein; Simental-Mendía, Luis E; Katsiki, Niki; Reiner, Željko; Banach, Maciej; Pirro, Matteo; Atkin, Stephen L

Citirajte ovaj rad

Sahebkar, A., Simental Mendía, L. E., Katsiki, N., Reiner, Ž., Banach, M., Pirro, M. i Atkin, S. L. (2019). Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open, 8. (11). doi: 10.1136/bmjopen-2018-021508

Sahebkar, Amirhossein, et al. "Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials." BMJ Open, vol. 8, br. 11, 2019. https://doi.org/10.1136/bmjopen-2018-021508

Sahebkar, Amirhossein, Luis E Simental Mendía, Niki Katsiki, Željko Reiner, Maciej Banach, Matteo Pirro i Stephen L Atkin. "Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials." BMJ Open 8, br. 11 (2019). https://doi.org/10.1136/bmjopen-2018-021508

Sahebkar, A., et al. (2019) 'Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials', BMJ Open, 8(11). doi: 10.1136/bmjopen-2018-021508

Sahebkar A, Simental Mendía LE, Katsiki N, Reiner Ž, Banach M, Pirro M, i sur.. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open [Internet]. 22.02.2019. [pristupljeno 09.05.2024.];8(11). doi: 10.1136/bmjopen-2018-021508

A. Sahebkar, et al., "Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials", BMJ Open, vol. 8, br. 11, Veljača 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:905720. [Citirano: 09.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:905720
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
AutorAmirhossein Sahebkar
AutorLuis E Simental-Mendía
AutorNiki Katsiki
AutorŽeljko Reiner
AutorMaciej Banach
AutorMatteo Pirro
AutorStephen L Atkin
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
OBJECTIVES: This meta-analysis of randomised placebo-controlled clinical trials aimed to assess the effect of fenofibrate on apolipoprotein C-III (apo C-III), a key regulator of triglyceride metabolism. ----- MATERIALS AND METHODS: Randomised placebo-controlled trials investigating the impact of fenofibrate treatment on apo C-III levels were searched in PubMed-Medline, Scopus, Web of Science and Google Scholar databases from inception to 18 August 2017. Quantitative data synthesis was determined by a random-effects model and generic inverse variance method. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate glycaemic parameter confounders. ----- RESULTS: Meta-analysis of 10 clinical trials involving 477 subjects showed fenofibrate therapy decreased apo C-III levels (weighted mean difference (WMD) -4.78 mg/dL, 95% CI -6.95 to -2.61, p<0.001; I266.87%). Subgroup analysis showed that fenofibrate reduced plasma apo C-III concentrations in subgroups of trials with treatment durations of either <12 weeks (WMD -4.50 mg/dL, p=0.001) or ≥12 weeks (WMD: -4.73 mg/dL, p=0.009) and doses of fenofibrate <200 mg/day (WMD -6.33 mg/dL, p<0.001) and >200 mg/day (p=0.006), with no significant difference between the subgroups. ----- CONCLUSION: This meta-analysis found that fenofibrate therapy significantly decreases apo C-III levels, an effect evident with both short-term treatment and doses less than 200 mg/day.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBMJ Open
Brojčani podacivol. 8, br. 11, e021508
p-ISSN2044-6055
DOIhttps://doi.org/10.1136/bmjopen-2018-021508
URN:NBNurn:nbn:hr:105:905720
Datum objave publikacije2019-02-22
URL dokumentahttps://doi.org/10.1136/bmjopen-2018-021508
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:54:33